NCT03390504 2026-02-02THORJanssen Research & Development, LLCPhase 3 Active not recruiting629 enrolled 32 charts 1 FDA
NCT02365597 2026-01-30An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerJanssen Research & Development, LLCPhase 2 Active not recruiting239 enrolled 32 charts 1 FDA